Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Clin Pharmacol Ther
2011 Jun 01;896:816-20. doi: 10.1038/clpt.2011.42.
Show Gene links
Show Anatomy links
Environmental and genetic factors affecting transport of imatinib by OATP1A2.
Eechoute K
,
Franke RM
,
Loos WJ
,
Scherkenbach LA
,
Boere I
,
Verweij J
,
Gurney H
,
Kim RB
,
Tirona RG
,
Mathijssen RH
,
Sparreboom A
.
???displayArticle.abstract???
The bioavailability of orally administered imatinib is >90%, although the drug is monocationic under the acidic conditions in the duodenum. In vitro, we found that imatinib is transported by the intestinal uptake carrier organic anion transporting polypeptide (OATP1A2) and that this process is sensitive to pH, rosuvastatin, and genetic variants. However, in a study in patients with cancer, imatinib absorption was not associated with OATP1A2 variants and was unaffected by rosuvastatin. These findings highlight the importance of verifying in a clinical setting the drug-transporter interactions observed in in vitro tests.
Badagnani,
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants.
2006, Pubmed,
Xenbase
Badagnani,
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants.
2006,
Pubmed
,
Xenbase
Burger,
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
2004,
Pubmed
Demetri,
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
2009,
Pubmed
Eechoute,
Drug transporters and imatinib treatment: implications for clinical practice.
2011,
Pubmed
Franke,
Pharmacogenetics of the organic anion transporting polypeptide 1A2.
2009,
Pubmed
Gardner,
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
2006,
Pubmed
Giacomini,
Membrane transporters in drug development.
2010,
Pubmed
Glaeser,
Intestinal drug transporter expression and the impact of grapefruit juice in humans.
2007,
Pubmed
Hamada,
Interaction of imatinib mesilate with human P-glycoprotein.
2003,
Pubmed
Ho,
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
2006,
Pubmed
Hu,
Interaction of imatinib with human organic ion carriers.
2008,
Pubmed
,
Xenbase
Huang,
ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.
2006,
Pubmed
Judson,
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
2005,
Pubmed
Kitamura,
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
2008,
Pubmed
Laitinen,
Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
2011,
Pubmed
Larson,
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
2008,
Pubmed
Lee,
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.
2005,
Pubmed
Martin,
Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
2003,
Pubmed
McTaggart,
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
2001,
Pubmed
Meyer zu Schwabedissen,
Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer.
2008,
Pubmed
Peng,
Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.
2004,
Pubmed
Picard,
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
2007,
Pubmed
Schachter,
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
2005,
Pubmed
Szakács,
Acid-base profiling of imatinib (gleevec) and its fragments.
2005,
Pubmed
Widmer,
Imatinib plasma levels: correlation with clinical benefit in GIST patients.
2010,
Pubmed
